SCHEMBL30201185

SCHEMBL30201185

CC(CNC(=N)CNc1ccccc1)OCc1cccc(Cl)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.43
ADRB2 P07550 3/20 0.43
ADRB3 P13945 3/20 0.43
ADRB1 P08588 2/20 0.43
MEN1 O00255 1/20 0.41
GAA P10253 1/20 0.41
KMT2A Q03164 1/20 0.41
RAB9A P51151 1/20 0.40
LMNA P02545 3/20 0.39
ALDH1A1 P00352 3/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
TACR1 P25103 2/20 0.38
GID4 Q8IVV7 1/20 0.38
HPGD P15428 2/20 0.37
PLA2G1B P04054 1/20 0.37
ATG4B Q9Y4P1 1/20 0.37
ENPP2 Q13822 1/20 0.37
F2 P00734 1/20 0.36
F7 P08709 1/20 0.36
CYP3A4 P08684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30201297 0.85 MEN1 (0.47) MAOBMEN1GAAKMT2ARAB9A
SCHEMBL30201055 0.82 ALDH1A1 (0.47) ADRB2ADRB3ADRB1KMT2ARAB9A
Formic Acid SCHEMBL30201032 0.78 ALDH1A1 (0.46) ADRB2ADRB3ADRB1KMT2ARAB9A
SCHEMBL30201042 0.73 MTNR1A (0.56) MEN1GAAKMT2ARAB9ALMNA
SCHEMBL30200879 0.72 MTNR1A (0.55) MEN1KMT2ARAB9ALMNAALDH1A1
SCHEMBL30201393 0.71 MTNR1A (0.48)
SCHEMBL30200758 0.70 MTNR1A (0.47) KMT2ALMNAALDH1A1L3MBTL1
SCHEMBL30201017 0.69 MTNR1A (0.45) LMNAALDH1A1L3MBTL1
SCHEMBL30201037 0.68 DRD2 (0.54) MAOBMEN1GAAKMT2ARAB9A
SCHEMBL30200979 0.68 MTNR1A (0.47) MEN1KMT2AALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240390301-A1 COMBINATIONS OF PERIPHERAL 5-HT2A RECEPTOR ANTAGONISTS AND CENTRAL 5-HT2A RECEPTOR AGONISTS GILGAMESH PHARMACEUTICALS, INC. (US) 2024-11-28 US disclosed
WO-2023028086-A1 COMBINATIONS OF PERIPHERAL 5-HT2A RECEPTOR ANTAGONISTS AND CENTRAL 5-HT2A RECEPTOR AGONISTS GILGAMESH PHARMACEUTICALS, INC. (US) 2023-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240390301-A1 COMBINATIONS OF PERIPHERAL 5-HT2A RECEPTOR ANTAGONISTS AND CENTRAL 5-HT2A RECEPTOR AGONISTS HTR2A, HTR2C, HTR5A MAOB 169/4885ADRB2 102/4885ADRB3 195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.